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Objective: The present observational cohort study documented the safety of ago-
melatine in current medical practice in out‐patients suffering from major depressive
disorder.
Method: The 6‐month evolution of agomelatine‐treated patients was assessed with
a focus on safety (emergent adverse events, liver acceptability), severity of
depression using the Clinical Global Impression Severity (CGI‐S) score, and func-
tioning measured by the Sheehan Disability Scale (SDS).
Results: A total of 8453 depressed patients from 761 centres in 6 countries were
analysed (female: 67.7%; mean age: 49.1 � 14.8 years). Adverse events reported
were in accordance with the known safety profile of agomelatine. Cutaneous events
were reported in 1.7% of the patients and increased hepatic transaminases values
were reported in 0.9 % of the patients. The incidence of events related to suicide/
self‐injury was 1.0%. Two completed suicides, not related to the study drug, were
reported. CGI‐S total scores and SDS sub‐scores improved and numbers of days lost
or underproductive decreased over the treatment period.
Conclusions: In standard medical practice, agomelatine treatment was associated
with a low incidence of side effects. No unexpected events were reported. A decrease
in the severity of the depressive episode and improved functioning were observed.
Trial registration name: Observational cohort study to evaluate the safety of
agomelatine in standard medical practice in depressed patients. A prospective,
observational (non‐interventional), international, multicentre cohort study.
Trial registration number: ISRCTN53570733
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1 | INTRODUCTION
Major depressive disorder (MDD) is the most common psychiatric
disorder worldwide, with a lifetime prevalence of approximately 13%
(Alonso et al., 2004; Bromet et al., 2011; Ferrari et al., 2013), asso-
ciated with marked morbidity and premature mortality (Chesney,
Goodwin, & Fazel, 2014). The antidepressant agomelatine (Val-
doxan®) is a melatonergic MT1/MT2 receptor agonist with serotonin
5‐HT2C receptor antagonist activity (Guardiola‐Lemaitre et al.,
2014). With this unique mechanism of action, agomelatine has
demonstrated a range of properties that suggest it could offer
advantages over current treatments for MDD (Kennedy & Rizvi,
2010). The antidepressant efficacy of agomelatine has been
demonstrated at doses of 25–50 mg in the treatment of the full
range of depressive symptoms in patients with moderate to severe
MDD (de Bodinat et al., 2010) and agomelatine showed a similar
efficacy to other available treatments (Taylor, Sparshatt, Varma, &
Olofinjana, 2014).
Agomelatine is generally well tolerated and shows a different
profile of adverse events compared to selective serotonin reuptake
inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitor
(SNRIs), with a more favourable profile on gastrointestinal, psychi-
atric, cutaneous and vascular systems (Kennedy & Rizvi, 2010).
Agomelatine also preserves the integrity of sexual function (Montejo
et al., 2010, 2015) and is not associated with discontinuation syn-
drome after abrupt treatment cessation (Montgomery, Kennedy,
Burrows, Lejoyeux, & Hindmarch, 2004). Nevertheless, cases of liver
transaminases increase (AST/ALT > 3 ULN in 1.25% on agomelatine
25 mg, 2.62% on 50 mg, 0.5% of patients on placebo—Summary of
product characteristics (SmPC) have been reported in agomelatine‐
treated patients and in post marketing settings only, rare cases of
hepatic failure were observed; therefore, a liver monitoring scheme is
required and the drug is contraindicated in patients with impaired
liver function.
At time of the product launch, in 2009, incidences of skin
emergent adverse events were similar in agomelatine and placebo
groups (1.17 and 1.25 per 100 patient‐months respectively). Skin
reactions were however considered as a potential risk to be further
monitored, based on the report of two serious cases (erythema
nodosum recovered under treatment; erythematous rash) on
agomelatine treatment.
In parallel, in depressed patients, the risk of suicide being high
(American Psychiatric Association, 2003) this risk must be monitored.
As treatment proceeds, variations in depressive symptoms may be
associated with fluctuations in suicide risk. This monitoring includes
evaluation of the presence of suicidal ideation and behaviours
(American Psychiatric Association, 2010).
The current cohort study was designed to evaluate, in conditions
of standard medical practice, the safety of a treatment with agome-
latine prescribed to depressed patients. A focus was made on hepatic
disorders (hepatic events with or without clinical symptoms including
increase of transaminases >3 ULN), skin events, and suicidality
(suicidal ideations, behaviours, and acts).
2 | METHODS
2.1 | Patients and study design
This was a prospective, observational, international, multi‐centre
cohort study conducted in depressed patients followed‐up in current
medical practice for their current depressive episode. The study was
conducted in 761 centres in 6 countries. The physicians were
recruited firstly through hospitals, clinics or private practices, in the
speciality of psychiatry, then in the general practice.
Inclusion criteria were: male or female patients, more than 18
years of age, initiating agomelatine treatment for their current
depressive episode, having signed an informed consent and accepting
to give a personal reference contact.
Prescription of agomelatine resulted from a normal clinical
evaluation according to the physician's clinical judgement, based on
each patient's clinical profile and in line with the SmPC, including
contra‐indications, special warning and precautions for use. The
decision to enter a patient in the study, after his/her agreement, was
done after the clinical decision to prescribe agomelatine.
Patients were not enrolled if they participated in another study,
if they had to stop a successful on‐going antidepressant treatment, if
they wished to continue another antidepressant treatment in addi-
tion to agomelatine, or if they planned to move during the follow‐up
period of the study. No exclusion criteria were defined on potential
comorbidities.
Patients were followed during 26 weeks of treatment with the
usual clinical follow‐up provided by the involved clinicians. In case of
agomelatine discontinuation, an end‐of‐study visit was scheduled 2
weeks after agomelatine withdrawal to follow safety and withdrawal
symptoms.
For each patient, the dose and the duration of treatment were
individually decided by the participating physician according to their
usual medical practice, based on the approved SmPC and patients'
clinical profiles. The starting dose of agomelatine was 25 mg once
daily. A dose increase from 25 to 50 mg/day could be decided by the
investigator. Patients who reported a dose of 25 mg/day throughout
their follow‐up were considered in the ‘agomelatine 25 mg’ subgroup;
patients with at least one intake of 50 mg were considered in the
‘agomelatine 25–50 mg’ subgroup.
2.2 | Measurements
Physical examination and vital signs (heart rate, blood pressure, and
weight) were assessed according to the usual care practice at base-
line, follow‐up and end‐of‐study visits. Emergent adverse events
(EAEs), including skin events (SOC), were collected at each visit and
were defined as events occurring after the first study drug intake and
up to 30 days after the last intake.
The report of adverse event was spontaneous. Physicians had to
make sure that any adverse event/reaction or worsening of
depression that occurred during the study was recorded. In
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particular, exacerbation of symptoms related to depression, including
anxiety or other isolated symptoms possibly related to lack of effi-
cacy of the study treatment or to cessation of treatment were to be
recorded.
Liver function tests had to be performed as recommended in the
agomelatine SmPC. Liver acceptability was assessed on both bio-
logical hepatic parameters with a focus on cases of aspartate
aminotransferase (AST) and/or alanine aminotransferase (ALT) >3
ULN (upper limit of normal), and adverse events in accordance with
investigator's judgement, link or not to biological abnormalities. For
any AST and/or ALT > 3x ULN or evocating signs of hepatotoxicity,
an adverse event had to be reported. A clinical review of narratives
of all patients presenting with potentially clinically significant
transaminases elevations (AST or ALT > 3 ULN) was made by
a Liver Safety Committee composed of four hepatologists and a
medical internist in order to assess causality of the reported
abnormalities.
Suicidality (suicide, suicide attempt, suicidal ideation and self‐
injuries behaviour) was assessed through the analysis of adverse
events and using the Mini‐International Neuropsychiatric Interview
(M.I.N.I.) items all along the study. Reviewing and adjudication pro-
cedures were set up and, in cases of serious suicidal behaviour
(completed suicide or suicide attempt), were supervised by an
external independent expert.
At each visit (baseline, follow‐up and end‐of‐study visits), the
investigator assessed the severity of depression using the Clinical
Global Impression (CGI; Guy, 1976, pp. 217–222) severity of illness
(CGI‐S), and the patients' functioning using the Sheehan Disability
Scale (SDS; Sheehan, Harnett‐Sheehan, & Raj, 1996). No other psy-
chometric assessment tool was used as it was a non‐interventional
study.
2.3 | Statistical analysis
Quantitative variables were described by number of valid data, mean
value and standard deviation. For qualitative variables, absolute and
relative frequency distributions were presented.
Statistical analysis was performed on SAS® software, version 9.2.
The study was run in accordance with the principles stated in the
Declaration of Helsinki, Finland, Good Pharmacoepidemiology Prac-
tices (ISPE, 2008), Ethical Guidelines for Epidemiological, Studies
(Rose, 2009) and the applicable regulatory requirements.
3 | RESULTS
3.1 | Baseline data
The study involved 1205 physicians from 761 centres in France
(n ¼ 265), Germany (n ¼ 168), Italy (n ¼ 105), Netherlands (n ¼ 22),
Portugal (n ¼ 47) and Spain (n ¼ 154), from December 2009 to
August 2014.
Psychiatrists recruited 60.1% of patients, while general practi-
tioners recruited 39.9% of patients. Of the 8743 patients included,
8453 patients with a signed inform consent and a date of agomela-
tine first intake were included in the analysis.
Out of the patients excluded due to unavailable signed informed
consent, 14 patients reported at least one adverse event and were
thus included in the safety cohort, which therefore consisted of 8467
patients. Main baseline characteristics of patients are presented in
Table 1a. Patients had been depressed for more than 9 years in
average and had a mean number of two major depressive episodes,
including the current one. Based on the M.I.N.I. suicidality items,
34.4% of patients had a suicidal risk, most (15.7%) at a low level, 7.8%
at a moderate level and 7.3% at a severe level of risk. Almost half of
the patients reported at least one concomitant disease at inclusion.
The most frequently reported comorbidities were hypertension,
hypercholesterolemia, hypothyroidism, anxiety and diabetes mellitus
(Table 1b).
The mean CGI‐S was 4.5 � 0.9 (median: 5, markedly ill) and
according to the SDS, on average, the patients felt moderately
disrupted by disease symptoms and those linked to potential side
effects for those on antidepressant treatments for the 3 functional
domains.
3.2 | Patient disposition
Most patients (76.1%) were treated with agomelatine 25 mg,
whereas 23.9% of patients were treated with agomelatine 25–50 mg.
Patients treated with the 25–50 mg dose had more severe depressive
disorders and a higher disability at baseline than patients treated
with the 25 mg fixed dose (e.g., in terms of disease duration, number
of depressive episodes, hospitalizations and suicidal risk; Table 1c).
The mean treatment duration was 5.8 � 2.9 months; 60.1% of
patients being treated with agomelatine for at least 6 months.
Treatment duration was similar in patients treated with the 25 mg
dose (5.7 � 2.9 months) and patients treated with the 25–50 mg dose
(6.3 � 2.7 months).
A total of 2978 of patients (35.2%) were withdrawn from the
study. The main reasons were remission or marked improvement
(12.4% of patients), adverse event (8.6%), lack of efficacy (7.2%) and
non‐medical reason (3.9%); 67 patients (0.8%) did not come back for
the end‐of‐study visit. Out of the patients withdrawn from the study,
2829 (95%) stopped agomelatine, including 786 patients (27.8%) who
switched to another antidepressant treatment, as 5.0% of patients
remained on agomelatine treatment.
During the study period, 67% of patients treated by agomelatine
(65.3% in the 25 mg fixed group and 72.3% in the 25–50 mg group)
received at least one psychotropic concomitant treatment, anxio-
lytics (26.2% of patients) being the most common.
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4 | SAFETY RESULTS
4.1 | Adverse events
The percentages of patients who reported at least one emergent
adverse event (EAE) on treatment was 27.8%. The most frequently
affected system organ classes were psychiatric disorders (8.7%),
nervous system disorders (6.9%), infections and infestations (5.6%),
and gastrointestinal disorders (5.2%). The most frequent EAEs were
headache, nausea, anxiety and insomnia (Table 2a). EAEs were
considered as serious in 5.1% of patients and led to study treatment
withdrawal in 7.7% of patients, mainly due to psychiatric and nervous
system disorders (Table 2b).
During the study, 22 patients (0.3%) died, among them 16 were
aged 65 or older. The most frequent causes were related to infections
and infestations (6 patients; 27.3%), general disorders malignant
neoplasms, and respiratory, thoracic and mediastinal disorders
(5 patients each; 22.7%). A sudden death occurred 2 months after the
first agomelatine intake in a paraplegic patient; a cardiac arrest
occurred in a patient with a severe motoneuron disease. Two patients
completed suicide (vide supra). No death was considered related to
the study treatment neither by the investigator nor by the sponsor.
4.2 | Hepatic disorders
Hepatic EAEs, whatever the presence, nature or level of biological
abnormalities, were reported for a total of 196 out of 8467 patients
(2.3%).
The incidence was 2.0% with the 25 mg fixed dose and 3.3% with
the 25–50 mg dose. The most frequent EAE was ‘ALT increased’
(1.3% of patients). ‘GGT increased’ and ‘AST increased’ were also
reported (0.7% each).
Of note, among the 196 patients with emergent adverse events
related to hepatic disorders, 139 (71%) did not present with trans-
aminases increases >3x ULN.
TAB L E 1A Baseline characteristics of patients
Agomelatine cohort (N ¼ 8453)
Age (mean � SD; years) 49.1 � 14.8
Male/female (%) 32.3/67.7
Body mass index (mean � SD) 25.5 � 4.9
Number depressive episodes (including current one; mean � SD) 2.0 � 1.9
Disease duration (mean � SD; years) 9.2 � 9.5
Current episode duration (mean � SD; months) 6.7 � 14.7
Concomitant diseases (%) 46.7
CGI severity of illness score (mean � SD) 4.5 � 0.9
SDS total score (mean � SD) 16.4 � 5.9
SDS work (mean � SD) 6.0 � 2.4
SDS social life (mean � SD) 6.2 � 2.1
SDS family life (mean � SD) 6.0 � 2.2
Days unproductivea (mean � SD) 4.1 � 2.6
Days lost (mean � SD) 2.8 � 2.8
Abbreviations: CGI, Clinical Global Impression; SD, standard deviation; SDS, Sheehan Disability Scale.
aPatients felt so impaired by symptoms that their activity at school or at work was reduced.
TAB L E 1B Concomitant diseases at selection (reported in at
least 1.5% of MDD patients in the cohort)
PT
Agomelatine
cohort (N ¼ 8453)
All n (%) 3944 (46.7)
Hypertension n (%) 1197 (14.2)
Hypercholesterolaemia n (%) 445 (5.3)
Hypothyroidism n (%) 284 (3.4)
Anxiety n (%) 257 (3.0)
Diabetes mellitus n (%) 240 (2.8)
Osteoarthritis n (%) 227 (2.7)
Insomnia n (%) 173 (2.0)
Obesity n (%) 154 (1.8)
Asthma n (%) 144 (1.7)
Type 2 diabetes mellitus n (%) 137 (1.6)
Alcoholism n (%) 123 (1.5)
Osteoporosis n (%) 129 (1.5)
Note: n, number of patients with the described concomitant disease.
Percentage ¼ (n/N) � 100.
Abbreviation: MDD, major depressive disorder.
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TAB L E 1C Baseline characteristics of MDD patients in the cohort by dose of agomelatine
Agomelatine 25 mg
fixed (N ¼ 6431)
Agomelatine 25–50 mg
(N ¼ 2022)
Duration of the disease (mean � SD; years) 8.9 � 9.4 10.1 � 9.7
Number of depressive episodes (including present one; mean � SD) 1.9 � 1.8 2.3 � 2.2
Patients previously hospitalized for MDE (%) 7.5 12.8
Patients with previous treatment for depression (within 12 months; %) 28.4 37.3
Suicidal risk (%) 16.1 23.6
Patients with previous suicide attempts (%) 7.3 13.2
Suicidality scale (MINI; %) 29.2 40.7
Days unproductive (mean � SD) 4.0 � 2.6 4.6 � 2.5
Days lost (mean � SD) 2.7 � 2.7 3.1 � 2.8
Abbreviations: MDD, major depressive disorder; MINI, Mini‐International Neuropsychiatric Interview; SD, standard deviation.
TAB L E 2A EAEs reported in at least











n % n % n %
ALL 2351 27.8 1703 26.4 648 32.0
Depression 229 2.7 127 2.0 102 5.0
Headache 213 2.5 151 2.3 62 3.1
Nausea 175 2.1 146 2.3 29 1.4
Anxiety 155 1.8 112 1.7 43 2.1
Insomnia 140 1.7 100 1.6 40 2.0
Alanine aminotransferase increased 107 1.3 68 1.1 39 1.9
Dizziness 102 1.2 80 1.2 22 1.1
Restlessnes 65 0.8 44 0.7 21 1.0
Fatigue 65 0.8 38 0.6 27 1.3
Gamma‐glutamyltransferase increased 62 0.7 42 0.7 20 1.0
Aspartate aminotransferase increased 61 0.7 37 0.6 24 1.2
Suicidal ideation 56 0.7 31 0.5 25 1.2
Note: n, Number of patients with at least one EAE in a given level. Percentage (n/N)*100.
Abbreviation: EAE, emergent adverse events.
TAB L E 2B Type of emergent adverse events in the agomelatine safety cohort, per dose of agomelatine, and in the subset of patients aged
≥65 years









Serious EAE n (%) 433 (5.1) 278 (4.3) 155 (7.6) 86 (6.8)
Severe EAE n (%) 293 (3.5) 194 (3.0) 99 (4.9) 55 (4.4)
EAE related to treatment
n (%)
761 (9.0) 559 (8.7) 202 (10.0) 111 (8.8)
Withdrawal due to EAE
n (%)
651 (7.7) 550 (8.5) 101 (5.0) 121 (9.6)
Note: n, Number of patients with at least one EAE of the described type. Percentage (n/N)*100.
Abbreviation: EAE, emergent adverse events.
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Emergent hepatic disorders led to study drug withdrawal in 72
patients (36.7% of patients with events, i.e., 0.9% of the Agomelatine
Safety Cohort). In about half of the patients with emergent hepatic
disorders (99/196, 50.5%, i.e., 1.2% of the Agomelatine Safety
Cohort) these EAEs were considered as treatment related by the
investigators. All hepatic EAEs considered as study treatment‐related
by the investigators were listed in the Reference Safety Information
except one hepatic steatosis and 3 liver disorders (1 liver intolerance,
and 2 minor increases in liver values of which one was presumably
preexisting fatty liver).
Biological abnormalities were evaluated in patients with at least
one post‐baseline value of ALT or AST, that is, 6687 patients (79.0%
of the cohort) of whom 57 (0.9%) had at least one AST and/or ALT >
3 ULN (Table 3). Among those 57 patients, 54.4% had values between
3 ULN and 5 ULN, 28.1% had values between 5 ULN and 10 ULN, and
17.5% had values >10 ULN. Agomelatine was discontinued in 48
patients, temporarily interrupted in 3 patients (according to SmPC),
and the dose was reduced in 2 patients, the study drug being main-
tained in 4 patients of whom 3 recovered on treatment. At the last
available laboratory test, 37 out of 57 patients (64.9%) with trans-
aminases values >3 ULN recovered, 8 patients (14.0%) were recov-
ering between 1 and 2 ULN, 4 patients (7.0%) were recovering
between 2 ULN and 3 ULN, and 6 patients (10.5%) did not recover.
These transaminases increase occurred mainly within the first
3 months of treatment for 36 out of 57 patients. Among the ten
patients who had transaminases value >10 ULN (7 patients on ago-
melatine 25 mg, 3 on agomelatine 25–50 mg), 5 cases occurred in a
context of biliary colic associated with concomitant increase in total
bilirubin above 2 ULN (2 patients), alcohol intoxication (2 patients), or
intake of concomitant hepatotoxic treatment (1 patient). After
reviewing of the 10 cases by the Liver Safety Committee, to assess
the causality of the abnormalities, 3 cases were considered as
probably related to agomelatine, 3 possibly related to agomelatine,
1 unlikely related to agomelatine, and 3 not related to agomelatine.
All cases recovered.
No hepatic failure with fatal outcome, or resulting in liver
transplantation, was reported.
4.3 | Suicidality
A total of 85 patients (1.0%) reported at least one emergent event
related to suicide/self‐injury. Suicidal ideation and suicide attempt
were the most commonly reported (56 patients, 0.7% and 23 pa-
tients, 0.3%, respectively) and were more frequent with the 25–50
mg dose; they were notified as serious in 80% of patients and led to
treatment withdrawal in 46% of patients. The event occurred firstly
within the first month of treatment for 26 out of 85 patients (30.6%)
and in the second month for 17 patients (20.0%). All but one patient
with suicidal ideation had relevant medical history and/or triggering
factors (Table 4).
Two patients completed suicide. One 30‐year‐old patient, with
bipolar disorder history and 6 previous suicide attempts, treated for
18 days with the 25 mg dose, completed suicide 21 days after having
decided to stop treatment. One 39‐year‐old patient with impulsive
personality treated with the 50 mg dose completed suicide after
3 months of treatment. The patient had a high risk of suicide
according to MINI suicidality scale at baseline. All cases of completed
suicides and suicide attempts (24 cases) were reviewed by an expert:
events were judged not related to the agomelatine treatment in
17 patients and doubtfully related in 7 patients. According to the
expert's judgement, all these cases are particularly eloquent of the
scientific literature on the topic of treatment emergence or wors-
ening of suicidal behaviour. Whatever the delay of occurrence of the
suicidal act after the initiation of the treatment, all the patients were
carrying many risk factors, particularly a past history of suicide
attempt, a significant suicide risk at baseline and were difficult to
treat (comorbidities, lack of response to previous treatments, family
conflicts). This explains why it cannot be assumed that any of the
described cases may be directly attributable to the antidepressant
investigated. Patients aged <30 years were not at increased suicidal
risk (incidence rate: 0.7%).
4.4 | Skin reaction
A total of 144 patients (1.7%) reported at least one EAE in the skin
and subcutaneous tissue disorders (MEDRA, System Organ Class),
without dose related effect (1.8% and 1.4% in 25 mg and 25/50 mg
respectively). The most frequent (>10 patients) were hyperhidrosis
(28 patients, 19.4%), eczema (15 patients, 10.4%), alopecia, pruritus
and pruritic rash (11 patients for each, 7.6% each), except alopecia
these events are already listed for agomelatine. These events led to
study treatment withdrawal in 39 out of the 144 patients (27.1%;
0.5% of the whole cohort) and were considered as study treatment
related in 60 patients (41.6%; 0.7% of the cohort). For most patients
(81%,3%), the first event occurred within the first 3 months of
treatment. All but 5 out of 164 EAEs resolved (1 with sequelae: a
dermatitis) or were recovering at the cut‐off date; the 5 events
not resolved were 2 eczemas, 1 acne, 1 pruritus generalised and
1 hidradenitis (Table 5).
Serious skin reactions were reported in 10 patients, presenting
with 12 SAEs of which 2 were considered as severe (one case of cold
sweats and one decubitus ulcer). All the serious skin adverse events
were recovered or recovering at the end of the study.
4.5 | Patients aged 65 years or older
The percentages of patients who reported at least one EAE was
28.7%; serious EAEs were reported in 6.8% of patients (agomelatine
25 mg: 5.9%; agomelatine 25–50 mg: 10.9%).
Among patients aged 65 years or older, 36 (2.9%) reported at
least one emergent hepatic disorder. The incidence of emergent
abnormal AST and/or ALT value (1%) was similar as in the whole
cohort (Table 3).
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Patients aged ≥65 years were not at increased suicidal risk
(incidence rate: 0.7%).
Patients aged 65 years or older reported similar incidence rate of
skin reactions (2.1%) with one serious, a decubitus ulcer. The first
event occurred within the first 3 months of treatment (for 76.9% of
patients), 3 out of 30 skin events were not recovered, 2 eczema and
1 pruritus generalised.
5 | EFFECTIVENESS
5.1 | Functional improvement and CGI severity of
illness score
The mean CGI‐Severity illness scores decreased between baseline
(median: 5, markedly ill) and the last post‐baseline assessment (mean
change of   1.9 � 1.5).
For the three SDS sub scores, patients reported less symptom‐
related impairments over the treatment period in terms of work/daily
activities (mean change from baseline to last visit:   3.3 � 2.9), in
social life (  3.4 � 2.8), and in family life (  3.3 � 2.8). Numbers of
days lost and underproductive days were also diminished (mean
change from baseline to last visit:   1.7 � 2.8 and   2.6 � 2.8,
respectively; Table 6).
6 | DISCUSSION
Non‐interventional studies give the opportunity to obtain further
information on a medecine's safety in a real‐life situation without
selecting population as in clinical trials. The present observational
study aimed at evaluating the safety of agomelatine treatment in
current medical practice conditions and results confirm the known
tolerability profile of this drug (de Bodinat et al., 2010; Servier








Patients ≥ 65 years
(N ¼ 1256)




56 (0.66) 31 (0.48) 25 (1.23) 6 (0.5) 4 (0.5)
Suicide attempt
n (%)
23 (0.27) 11 (0.17) 12 (0.59) 3 (0.2) 2 (0.2)
Completed suicide
n (%)
2 (0.02) 1 (0.02) 1 (0.05) ‐ ‐
Note: n, Number of patients with at least one EAE. ‐, no case. Percentage (n/N)*100.
Abbreviation: EAE, emergent adverse events.
TAB L E 5 EAEs related to Skin and subcutaneous tissue disorders—Safety cohort and patients aged ≥ 65 years






n % n % n % n % n %
Safety cohort (N ¼ 8467) 144 1.7 7 0.1 10 0.1 39 0.5 60 0.7
Patients ≥ 65 years (N ¼ 1256) 26 2.1 3 0.2 1 0.1 8 0.6 7 0.6
Note: n, Number of patients with at least one EAE. Percentage (n/N)*100.
Abbreviation: EAE, emergent adverse events.












All n (%) 57 (0.9) 39 (0.8) 18 (1.0) 10 (1.0)
]3–5 ULN] n (%) 31 (0.5) 23 (0.5) 8 (0.5) 5 (0.5)
]5–10 ULN] n (%) 16 (0.2) 9 (0.2) 7 (0.4) 4 (0.4)
>10 ULN n (%) 10 (0.1) 7 (0.1) 3 (0.2) 1 (0.1)
Notes: N, number of patients with at least one post‐baseline ALT and/or AST value on treatment period. n, Number of patients with at least one event.
Percentage (n/N)*100.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal.
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Laboratories, 2015; Taylor et al., 2014). The analysed population was
a large cohort of patients from six European countries (8453 pa-
tients), patients' recruitment was almost balanced between psychia-
trists (60%) and general practitioners (40%); patients were markedly
ill according to CGI and had a moderate functioning impairment as
assessed by SDS; one‐third of patients presented a suicidal risk ac-
cording to M.I.N.I. suicidality evaluation. Uptitration to 50 mg was
required for 23.9% of patients, which is in line with the ratio
observed in agomelatine clinical trials (15%–35%); Kennedy & Ems-
ley, 2006). These patients had clinical characteristics of a medically
complex population to treat, with a higher disability and number of
previous depressive episodes and hospitalizations, and higher suicidal
risk for the current episode.
The mean treatment period by agomelatine was 6 months, during
which depressive symptoms improved according to CGI score, the
most common evaluation used in routine clinical practice (CGI‐S,
mean change of   1.9 � 1.5). Functionality in daily life was not
affected by drug acceptability as patient SDS scores improved in the
3 domains explored (work, social life, and family life & home re-
sponsibilities) and were associated with a decrease in the number of
underproductive or lost days.
During the study, no unexpected EAEs were reported in ago-
melatine‐treated patients: the nature and frequency of adverse
events reported were in accordance with previous knowledge ob-
tained during clinical trials development and comparable to the
known information on the product safety profile (Servier Labora-
tories, 2015). As expected, a more frequent report of serious EAEs
was described for the group of patients who required uptitration to
50 mg than in patients treated with the 25 mg fixed dose, a finding
likely related to the complex medical history of these patients. Similar
rates of EAE were reported in the whole population and in the subset
of patients aged 65 years and over. Overall, the acceptability profile
of agomelatine appears distinctly better than currently available
standard treatments, with discontinuations for side effects among
the lowest among second‐generation antidepressants (Cipriani
et al., 2018).
A focus was made on hepatic events related to the use
of agomelatine owing to the drug potential to elevate liver
enzymes. As regards transaminases increases (>3 ULN), a case‐
under‐treatment incidence of 0.8% at 25 mg dose and 1% at 25–50
mg dose were observed. These values are comparable to those
reported in the SmPC (1, 25% at 25 mg, 2, 62% at 50 mg). These
transaminases elevations (AST and/or ALT ≥ 3 ULN) were in ma-
jority within the range of ]> 3–5 ULN] (54%), mainly asymptomatic,
isolated and appeared mostly within the first 3 months. Unless
medical explanation (e.g., NASH, known history of liver injury),
most of liver function normalized within few weeks following
treatment discontinuation. Two Hy's law cases (two patients with
an increase in transaminases associated with cholelithiasis, both
not related to agomelatine) were reported, but no liver transplant,
TAB L E 6 SDS mean change from
baseline during agomelatine treatment.
Agomelatine cohort
Change between baseline and
last visit on treatment period ALL (N ¼ 8453)
Total score of SDS n 7338
Mean � SD   9.0 � 7.5
Min; Max   30; 24
Work/School n 4947
Mean � SD   3.3 � 2.9
Min; Max   10; 10
Social life n 7336
Mean � SD   3.4 � 2.8
Min; Max   10; 9
Family life and home responsibilities n 7337
Mean � SD   3.3 � 2.8
Min; Max   10; 10
Days lost n 7187
Mean � SD   1.7 � 2.8
Min; Max   7; 7
Days unproductive n 7151
Mean � SD   2.6 � 2.8
Min; Max   7; 7
Note: n, Number of patients with an available baseline and at least one available value on treatment
period.
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no fulminant hepatitis, no case of hepatic failure, and no hepatic
disorder with fatal outcome were observed. Whatever, in most
cases, patients are clinically asymptomatic and abnormal results on
liver function tests are the only elements that may raise a suspi-
cion of antidepressant‐induced liver injury. It should be mentioned
that in clinical trials, where serum transaminases are monitored
regularly, the risk is adequately minimized (Perlemuter et al., 2016)
with no emergence of severe symptomatic cases. As consequence,
the monitoring of transaminases values required since 2012 with
respect of contra indications are the most effective ways of mini-
mising hepatic risk. In general health care, such measures are
considered adapted to ensure an optimal follow‐up of depressed
patients (Voican et al., 2016). A recent analysis in a cohort
comprising 3.2 million new users of antidepressants has shown
that, in routine clinical practice, agomelatine did not increase the
risk of hospitalisation due to acute liver injury when compared to
citalopram (Pladevall‐Vila et al., 2019). As risk minimisation mea-
sures (compliance with relevant contra‐indications, precautions of
use, and biological liver testing before and during treatment) were
in place in the populations studied, this might contribute to the
lower risk found for agomelatine versus citalopram.
All antidepressant drugs may potentially cause hepatotoxic side
events, even at therapeutic doses, but antidepressant‐induced hep-
atotoxicity has been underestimated in the scientific literature, so the
evidence is insufficient for rigorous conclusions to be drawn about
the prevalence and severity of these events. Several antidepressants
including imipramine, amitriptyline, duloxetine, bupropion, trazo-
done, and agomelatine are associated with greater risks, whereas
citalopram, escitalopram, paroxetine, and fluvoxamine seem to have
the least potential for hepatotoxicity (Voican, Corruble, Naveau, &
Perlemuter, 2014). In real‐life practice, there is no evidence of an
increased risk of serious liver injury following initiation of SNRIs
(venlafaxine, milnacipran, duloxetine) or other antidepressants
(mianserin, mirtazapine, tianeptine and agomelatine) compared with
SSRIs (fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine, and
escitalopram; Billioti de et al., 2018).
A thorough evaluation of the patient's suicide risk has been
performed during the study. The incidence did not differ according to
the age of the patients (0.7% for patients aged <30 years or ≥65
years vs. 1.0% for patients aged <65 years) but was numerically more
elevated in the group of patients who required uptitration to 50 mg
(1.5% vs. 0.7% at 25 mg), a difference that can be due to more severe
depression characteristics at the start of treatment in the 25–50 mg
group. The two completed suicides were not considered related to
agomelatine.
In general, it is assumed that antidepressants are beneficial for all
symptoms of depression, including suicidality. Some evidence sug-
gests that antidepressant, including SSRIs, may cause worsening of
suicidal ideas in vulnerable patients, though systematic reviews and
pooled analysis of experimental, observational, and epidemiological
studies failed to provide a clear relationship between their use and
increased suicidal ideation and behaviour in adults (Nischal, Tripathi,
Nischal, & Trivedi, 2012). For all antidepressants, this risk can be
anticipated and managed clinically and there is a need for early
follow‐up and encouraging support and supervision of patients,
especially in the early phase of treatment.
The occurrence of cutaneous events was mentioned in the SmPC
at the time of agomelatine launch. Results of the present cohort
confirm that the frequency of these events did not differ according to
the dose prescribed (1.4% at 25–50 mg vs. 1.8% at 25 mg) or the age
of patients (2.1%, ≥65 years). Based on these cohort data, the
European Medical Agency (EMA) decided not to consider any more
skin events as a potential risk for agomelatine.
Cutaneous side effects have been described with all psychotropic
drugs; they are variable and numerous and usually benign, but may
occasionally carry significant morbidity (Bliss & Warnock, 2013;
Mitkov, Trowbridge, Lockshin, & Caplan, 2014).
The sustained adherence observed in this cohort study is in line
with the recommendations supporting duration of at least 6 months
of the treatment period to achieve a sufficient improvement of
symptoms and prevent the chronic evolution of the disease
(ANAES, 2002; Davidson, 2010; Mitchell, 2006; Qaseem, Snow,
Denberg, Forciea, & Owens, 2008; Wade, Despiegel, & Heldbo,
2006). It may be hypothesized that the level of adherence and the
observed efficacy of the agomelatine treatment are directly linked
to the good acceptability of the treatment by patients, hypothesis
supported by a low rate of treatment discontinuation due to AE in
the study.
A first limitation of this prospective study was that physicians
who accepted the study, compared to those who never answered or
refused, were probably more prone to work in accordance with
recommendations of treatment for depression or product SmPC.
Second, it cannot be ruled out that the duration of exposure has been
inflated by the recruitment of patients who were more compliant or
more concerned by the disease, and as such might more easily adhere
to the study medication. Finally, as a result of the non‐interventional
design, investigations were limited, thus no detailed information was
collected regarding the evolution of the different symptoms associ-
ated with depression.
The results of this international, observational, prospective, non‐
interventional study confirm under daily practice conditions the
safety profile of agomelatine given at the therapeutic recommended
doses. While patients' functioning and symptomatic distress were
improved by the treatment, collected safety data did not reveal any
new risk compared to those described in the SmPC and allowed a
more accurate assessment of potential risks in usual practice. These
findings obtained in a large representative population of out‐patients
suffering from MDD confirm the favourable tolerability profile of
agomelatine.
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